

a squirrel monkey immunized with liposomes as the control;

Figure 10G is a graph illustrating the percent parasitemia versus days post infection in a squirrel monkey immunized with physiological water as the control.

B²
corel.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS--.

Page 8, line 24, change "of" to --of--;

line 28, after "(LNVQTQ)" insert --(SEQ ID NO:15)--

Page 19, line 3, change "microtitre" to --microliter--

Please delete the Sequence Listing filed October 22, 1999, without prejudice.

Page 46 (Abstract), after the last line, beginning on a new page, please insert the attached substitute Sequence Listing.

IN THE CLAIMS

Please cancel Claims 1-45.

Please add the following Claims:

Sub 12
G1 ~~46. A baculovirus vector comprising a promoter, a synthetic polynucleotide encoding a 19 kilodalton C-terminal fragment of a *Plasmodium* MSP-1 protein; and wherein said synthetic polynucleotide has a GC content of 40 to 60%.~~

47. The baculovirus vector of Claim 46, wherein said synthetic polynucleotide is SEQ ID NO:1 or SEQ ID NO:7.

B⁴
Sub 12
G1 ~~48. The baculovirus vector of Claim 46, wherein said synthetic polynucleotide further comprises a glycosylphosphatidylinositol coding sequence.~~

Sub 13
G1 ~~49. The baculovirus vector of Claim 48, wherein said glycosylphosphatidylinositol is from a CD59 or CD14 gene.~~

50. The baculovirus vector of Claim 48, wherein said synthetic polynucleotide is SEQ ID NO:4.

Sub E 4
51. The baculovirus vector of Claim 46, wherein said synthetic polynucleotide further comprises a polynucleotide encoding a signal peptide.

52. The baculovirus vector of Claim 51, wherein said synthetic polynucleotide is SEQ ID NO:9.

53. The baculovirus vector of Claim 46, wherein said synthetic polynucleotide further comprises a polynucleotide encoding the *Plasmodium vivax* Duffy binding protein or the *Plasmodium falciparum* EBA-175 protein.

~~54. The baculovirus vector of Claim 46, wherein said Plasmodium is selected from the group consisting of *Plasmodium vivax*, *Plasmodium cynomolgi*, and *Plasmodium falciparum*.~~

Sub E 5
G14
B 4
cont.
~~55. The baculovirus vector of Claim 46 selected from the group consisting of PfMSP1p19A, PfMSP1p19S, and PcMSP1p19S.~~

56. A synthetic polynucleotide comprising a gene encoding the 19 kilodalton C-terminal fragment of a *Plasmodium* MSP-1 polypeptide; wherein said polynucleotide has a total GC content of 40 to 60%.

57. The synthetic polynucleotide of Claim 56, wherein said synthetic polynucleotide is SEQ ID NO:1 or SEQ ID NO:7.

Sub E 5
FS
58. ~~The synthetic polynucleotide of Claim 56, wherein said synthetic polynucleotide further comprises a glycosylphosphatidylinositol coding sequence.~~

Sub E 6
~~59. The synthetic polynucleotide of Claim 56, wherein said glycosylphosphatidylinositol is from a CD59 or CD14 gene.~~

60. The synthetic polynucleotide of Claim 58, wherein said synthetic polynucleotide

is SEQ ID NO:4.

Sub F7
61. ~~The synthetic polynucleotide of Claim 56, wherein said synthetic polynucleotide further comprises a polynucleotide encoding a signal peptide.~~

Sub E7
62. ~~The synthetic polynucleotide of Claim 61, wherein said synthetic polynucleotide is SEQ ID NO:9..~~

B4
correl.
63. The synthetic polynucleotide of Claim 56, wherein said synthetic polynucleotide further comprises a polynucleotide encoding the *Plasmodium vivax* Duffy binding protein or the *Plasmodium falciparum* EBA-175 protein.

64. The synthetic polynucleotide of Claim 56, wherein said Plasmodium is selected from the group consisting of *Plasmodium vivax*, *Plasmodium cynomolgi*, and *Plasmodium falciparum*.--
